Minnesota’s second year of 340B reporting shows that Covered Entities generated at least $1.34 billion in net 340B revenue in 2024, more than double the $630 million reported in 2023. The 340B Drug Pricing Program allows eligible safety net providers to buy outpatient drugs at a discount while receiving full reimbursement, but the program lacks transparency. In 2023, Minnesota became the first state to require 340B financial reporting to improve transparency in the rapidly expanding program.
In addition to the 112 percent increase between 2023 and 2024, the state’s largest 340B hospitals accounted for more than 80% of the statewide total, while Safety Net Federal Grantee clinics (such as FQHCs) generated the least. The report noted that the increase in reported revenue is largely due to more complete reporting of office administered drugs, however, it noted the $1.34 billion figure may still understate the program’s true size. Learn more here.
Last Updated on March 19, 2026 by Aimed Alliance
